Ha le, PA
Medical · Pahrump, NVNPI 1144491143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,890 of the $11,110 with a category attached, or 89.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$1K
- Amgen$976
- Biohaven Pharmaceuticals, Inc.$939
- AstraZeneca$904
- Intra-sana Laboratories$518
- plus $5K from 27 others
What the payments were for
- Consulting fees$8007%
- Food & beverage$9,89089%
- Education$4204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $1,667 |
| Novo Nordisk | 50 | $1,215 |
| Amgen(2 entities) | 24 | $976 |
| Biohaven Pharmaceuticals, Inc. | 3 | $939 |
| AstraZeneca | 29 | $904 |
| Intra-sana Laboratories | 28 | $518 |
| Boehringer Ingelheim | 21 | $489 |
| Lilly USA, LLC | 25 | $458 |
| AbbVie | 18 | $420 |
| Lucid Diagnostics Inc. | 12 | $342 |
| Dexcom, Inc. | 17 | $318 |
| Bayer | 16 | $313 |
| Boston Scientific | 4 | $300 |
| Daiichi Sankyo Inc. | 9 | $299 |
| Pfizer | 15 | $280 |
| Phathom Pharmaceuticals, Inc. | 9 | $279 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $261 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $226 |
| Exact Sciences | 9 | $148 |
| Axsome Therapeutics, Inc. | 2 | $144 |
| Nevro Corp. | 1 | $138 |
| Merck | 5 | $81 |
| Tactile Systems Technology Inc | 5 | $78 |
| Idorsia Pharmaceuticals US Inc | 3 | $56 |
| Corcept Therapeutics | 2 | $44 |
| GSK | 3 | $43 |
| Genentech USA, Inc. | 3 | $38 |
| Smith+Nephew | 1 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,049
- FreeStyle Libre 2$580
- Reltone 200 Mg$320
- GLYCATE$320
- Reltone 400 Mg$320
- FARXIGA$296
- PROCLAIM$289
- Repatha$255
- JARDIANCE$225
- FREESTYLE LIBRE 3$215
- BREZTRI$172
- AIRSUPRA$172
- BRILINTA$172
- INJECTAFER$150
- DEXCOM G7 GSS (161)$144
- DEXCOM STELO GLUCOSE BIOSENSOR$144
- Senza$138
- KRYSTEXXA$127
- CAPLYTA$127
- QULIPTA$124
How this compares
$11,110 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $121,685 |
| OzempicSemaglutide | 63 | $77,044 |
| EliquisApixaban | 48 | $45,174 |
| JardianceEmpagliflozin | 23 | $33,565 |
| XareltoRivaroxaban | 29 | $27,268 |
| SynjardyEmpagliflozin/Metformin Hcl | 20 | $22,252 |
| FarxigaDapagliflozin Propanediol | 15 | $22,214 |
| JanuviaSitagliptin Phosphate | 14 | $17,067 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $16,500 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,311 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,036 |
| TradjentaLinagliptin | 11 | $9,920 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,877 |
| KerendiaFinerenone | 12 | $7,068 |
| Pro Comfort Alcohol PadsAlcohol Antiseptic Pads | 50 | $5,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $458 | $121,68582 claims |
| Novo NordiskOzempic | $1,215 | $77,04463 claims |
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat, Tradjenta | $489 | $75,77369 claims |
| PfizerEliquis | $280 | $45,17448 claims |
| MerckJanuvia, Janumet | $81 | $33,56827 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $904 | $33,52429 claims |
| BayerKerendia | $313 | $7,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Pahrump
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.